NASDAQ:ATOS

Atossa Genetics Stock News

Healthcare > Biotechnology

Buy ATOS

*Your capital is at risk

$4.70

-0.150 (-3.09%)

At Close: Jun 03, 2026

Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering

09:45pm, Tuesday, 08'th Dec 2020

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of signifi

Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

09:30am, Friday, 13'th Nov 2020

SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of signifi

Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

09:30am, Tuesday, 10'th Nov 2020

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of signifi

New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic

07:03am, Wednesday, 28'th Oct 2020

SEATTLE, Oct. 28, 2020 /PRNewswire/ -- A paper published on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (

Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

01:30pm, Monday, 17'th Aug 2020

SEATTLE, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of signifi

Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

01:30pm, Thursday, 13'th Aug 2020

SEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of signifi

LD Micro Announces Preliminary List of Presenters for the LD-500.

03:04pm, Wednesday, 05'th Aug 2020

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin

The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans

12:00am, Tuesday, 04'th Aug 2020

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) ABIOMED, Inc. (NASDAQ: ABMD) ALX Oncology Holdings Inc (NASDAQ: ALXO) Annexon Inc (NASDAQ: ANNX) Atossa...

Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19

01:30pm, Monday, 03'rd Aug 2020

Enrollment Expected to Begin Within 30 daysSEATTLE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develo

Maxim Group Reaffirms Buy Rating for Atossa Genetics (NASDAQ:ATOS)

05:16am, Monday, 03'rd Aug 2020

Maxim Group reaffirmed their buy rating on shares of Atossa Genetics (NASDAQ:ATOS) in a report released on Friday, AnalystRatings.com reports. They currently have a $8.00 price objective on the stock.

Celyad Oncology annoncera prochainement les résultats financiers du premier semestre 2020 et tiendra une conférence téléphonique

12:00am, Monday, 03'rd Aug 2020

Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq : CYAD), une société de biotechnologie de stade

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by